U.S. Stem Cell, Inc.
USRM
$0.0001
$0.000.00%
| 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -59.14% | -70.73% | -57.06% | -54.08% | -27.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.14% | -70.73% | -57.06% | -54.08% | -27.57% |
| Cost of Revenue | -54.42% | -49.26% | -37.84% | -28.90% | -19.00% |
| Gross Profit | -60.75% | -75.56% | -61.74% | -60.45% | -30.14% |
| SG&A Expenses | -22.14% | -27.93% | -35.13% | -14.16% | -12.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.85% | -28.39% | -35.17% | -14.49% | -12.73% |
| Operating Income | 19.45% | 22.79% | 32.75% | 9.46% | 11.01% |
| Income Before Tax | 13.07% | 9.39% | 18.29% | -5.13% | -13.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.07% | 9.39% | 18.29% | -5.13% | -13.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.07% | 9.39% | 18.29% | -5.13% | -13.73% |
| EBIT | 19.45% | 22.79% | 32.75% | 9.46% | 11.01% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 30.56% | 26.03% | 29.41% | 5.26% | -5.88% |
| Normalized Basic EPS | 38.10% | 20.51% | 27.66% | 2.38% | 0.00% |
| EPS Diluted | 30.56% | 26.03% | 29.41% | 5.26% | -5.88% |
| Normalized Diluted EPS | 38.10% | 20.51% | 27.66% | 2.38% | 0.00% |
| Average Basic Shares Outstanding | 28.33% | 24.28% | 17.35% | 10.58% | 7.33% |
| Average Diluted Shares Outstanding | 28.33% | 24.28% | 17.35% | 10.58% | 7.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
